Conditions: Bladder Cancer; Non-Muscle Invasive Bladder Cancer (NMIBC); Urothelial Carcinoma; Carcinoma in Situ (CIS); High-Grade Papillary Bladder Tumors; BCG-Unresponsive Bladder Cancer; Ta Stage Bladder Cancer; T1 Stage Bladder Cancer; BCG-Refractory Bladder Cancer; High-Risk NMIBC; Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions: Drug: Intravesical Gemcitabine and Docetaxel
Sponsors: Michael A. O’Donnell
Not yet recruiting Conditions: Bladder Cancer; Non-Muscle Invasive Bladder Cancer (NMIBC); Urothelial Carcinoma; Carcinoma in Situ (CIS); High-Grade Papillary Bladder Tumors; BCG-Unresponsive Bladder Cancer; Ta Stage Bladder Cancer; T1 Stage Bladder Cancer; BCG-Refractory Bladder Cancer; High-Risk NMIBC; Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions: Drug: Intravesical Gemcitabine and Docetaxel
Sponsors: Michael A. O’Donnell
Not yet recruiting
